# IDEAYA Biosciences, Inc. (IDYA): Analyst Consensus Points to 86% Upside Potential

- Link: https://www.directorstalkinterviews.com/ideaya-biosciences-inc-idya-analyst-consensus-points-to-86-upside-potential/4121210866
- Published: 2025-08-05T10:35:52+01:00
- Author: Madison Wilson

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) stands at the forefront of the precision
medicine oncology sector, offering compelling prospects for investors looking to
capitalize on the biotechnology industry’s potential. This South San Francisco-based
company, founded in 2015, focuses on developing targeted therapeutics for patient
populations identified through molecular diagnostics, a niche that promises substantial
upside.

With a market capitalization of $2.19 billion, IDEAYA is well-positioned within 
the healthcare sector, particularly in the biotechnology industry. The company’s
current stock price hovers around $25, exhibiting minimal fluctuation with a recent
price change of just 0.03%. However, what truly catches the eye is the stock’s 52-
week range, which spans from $14.50 to a high of $39.80, suggesting significant 
volatility and investment potential.

Investors should note that traditional valuation metrics like the P/E ratio and 
PEG ratio are not applicable to IDEAYA, largely due to its developmental stage and
ongoing clinical trials. The forward P/E ratio stands at -8.09, indicating expectations
of future losses, which is not uncommon for biotech companies investing heavily 
in R&D. Furthermore, the company’s return on equity is currently at a negative 31.34%,
and its free cash flow is notably negative at -$164.6 million, reflecting its intensive
investment in its promising pipeline.

Despite these figures, IDEAYA’s portfolio is impressive, featuring multiple drug
candidates targeting specific genetic mutations. Among its leading products in development
are IDE196 and IDE397, both in advanced stages of clinical trials, alongside a suite
of other candidates targeting a range of cancers. Such innovative approaches have
attracted strategic alliances with major players like [GlaxoSmithKline](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l),
Pfizer, and Merck, underscoring the credibility and potential of IDEAYA’s scientific
endeavors.

From an analyst perspective, the company enjoys robust support. It boasts 14 buy
ratings and just two hold ratings, with no analysts recommending a sell. The average
target price set by analysts is $46.50, signifying an impressive potential upside
of 86% from its current trading price. This optimism is further supported by its
technical indicators; the stock is currently trading above both its 50-day and 200-
day moving averages, at $22.06 and $22.64 respectively, with a relative strength
index (RSI) of 60.68, suggesting the stock is neither overbought nor oversold.

While IDEAYA does not currently offer a dividend, the focus for investors should
remain on its growth potential and the eventual commercialization of its drug candidates.
The company’s alliances and partnerships with industry giants not only provide financial
support but also enhance credibility and potential for successful market entry.

For investors considering a stake in IDEAYA Biosciences, the key considerations 
should include the company’s innovative pipeline, strategic partnerships, and the
strong analyst consensus pointing to a significant upside. As with all biotech investments,
risks are inherent, particularly those associated with clinical trial outcomes and
regulatory approvals. However, for those with a higher risk tolerance, IDEAYA represents
a promising opportunity within the rapidly evolving field of precision medicine 
oncology.

Share on: